Acute lymphoblastic leukemia (ALL) presents as a complex disease encompassing diverse genomic subtypes with varying treatment responses and outcomes. Despite significant advancements, challenges persist, particularly in addressing treatment resistance and relapse, highlighting the urgent need for personalized therapeutic strategies.

Functional precision medicine approaches, integrating drug sensitivity profiling and genomic testing, offer promising avenues towards tailored treatment solutions. In this webinar, we introduce an innovative ex vivo drug sensitivity imaging-based platform tailored for primary ALL cells. Leveraging fluorescence imaging and mesenchymal stromal cell co-culture, this high-throughput assay enables the assessment of individual drug sensitivity profiles, overcoming previous limitations in cell count requirements and assay duration. By correlating drug sensitivity data with patient genomic profiles, attendees will explore the potential for subtype-specific therapeutic opportunities and actionable target discovery in ALL.

Highlights:

1. Understanding ALL Complexity and challenges in ALL treatment

2. Introduction of an ex vivo Drug Sensitivity Imaging-based Platform

3. Correlating Drug Sensitivity with Genomics

4. Implications for Precision Oncology